{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:48:43Z","timestamp":1780760923890,"version":"3.54.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["AstraZeneca"],"award-info":[{"award-number":["AstraZeneca"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Eosinophilic esophagitis (EoE), a chronic immune-mediated progressive disease, causes dysphagia, food impaction, abdominal pain, vomiting, and heartburn. EoE requires long-term monitoring and can affect quality of life owing to its symptoms and associated emotional and social burden. This study aimed to understand patients\u2019 experiences with EoE.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Semi-structured longitudinal interviews were conducted with patients from MESSINA, a phase 3 placebo-controlled trial evaluating benralizumab for EoE. Interviews were held at two different times to assess the impact of EoE on patients\u2019 lives before and during trial participation. Data were analyzed qualitatively to develop detailed patient profiles.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The MESSINA trial was terminated prematurely. Of the 34 patients recruited for the first interview, 15 (44%) completed the second interview and 11 patient profiles were developed. Patients were a demographically diverse group with varying experiences. The primary reported symptom was difficulty swallowing (<jats:italic>n<\/jats:italic>\u2009=\u200911), leading to serious consequences like choking and hospitalization (<jats:italic>n<\/jats:italic>\u2009=\u20092). Other symptoms included pain when swallowing (<jats:italic>n<\/jats:italic>\u2009=\u20097), reflux (<jats:italic>n<\/jats:italic>\u2009=\u20096), and stomachache (<jats:italic>n<\/jats:italic>\u2009=\u20096). In the second interview, most (<jats:italic>n<\/jats:italic>\u2009=\u20099) patients reported moderate improvements in symptoms, while others experienced symptom recurrence or worsening. EoE had a significant negative impact on social and emotional well-being, and professional lives. Trial participation improved emotional well-being for some; however, concerns about the need for ongoing treatment were noted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study highlighted emotional and social burdens of EoE. The encouraging feedback on study participation underscores the importance of patient insights in developing holistic management strategies for EoE.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-025-00836-x","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T09:52:56Z","timestamp":1736329976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Patient experience with eosinophilic esophagitis symptoms and impacts on daily life based on in-trial qualitative interviews"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3360-9651","authenticated-orcid":false,"given":"Calvin N.","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Fj\u00e4llbrant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan S.","family":"Dellon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilio","family":"Santander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc E.","family":"Rothenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehan","family":"McFadden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"issue":"8","key":"836_CR1","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1136\/gutjnl-2022-327326","volume":"71","author":"A Dhar","year":"2022","unstructured":"Dhar A, Haboubi HN, Attwood SE, Auth MKH, Dunn JM, Sweis R et al (2022) British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults. Gut 71(8):1459\u20131487. https:\/\/doi.org\/10.1136\/gutjnl-2022-327326","journal-title":"Gut"},{"issue":"3","key":"836_CR2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/2050640616689525","volume":"5","author":"AJ Lucendo","year":"2017","unstructured":"Lucendo AJ, Molina-Infante J, Arias \u00c1, von Arnim U, Bredenoord AJ, Bussmann C et al (2017) Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United Eur Gastroenterol J 5(3):335\u2013358. https:\/\/doi.org\/10.1177\/2050640616689525","journal-title":"United Eur Gastroenterol J"},{"key":"836_CR3","doi-asserted-by":"publisher","first-page":"101825","DOI":"10.1016\/j.bpg.2023.101825","volume":"62\u201363","author":"P Visaggi","year":"2023","unstructured":"Visaggi P, Baiano Svizzero F, Savarino E (2023) Food elimination diets in eosinophilic esophagitis: practical tips in current management and future directions. Best Pract Res Clin Gastroenterol 62\u201363:101825. https:\/\/doi.org\/10.1016\/j.bpg.2023.101825","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"20","key":"836_CR4","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.3390\/cells12202473","volume":"12","author":"S Massironi","year":"2023","unstructured":"Massironi S, Mulinacci G, Gallo C, Elvevi A, Danese S, Invernizzi P et al (2023) Mechanistic insights into eosinophilic esophagitis: therapies targeting pathophysiological mechanisms. Cells 12(20):2473. https:\/\/doi.org\/10.3390\/cells12202473","journal-title":"Cells"},{"issue":"1","key":"836_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jaci.2011.02.040","volume":"128","author":"CA Liacouras","year":"2011","unstructured":"Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA et al (2011) Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 128(1):3\u201320e6. https:\/\/doi.org\/10.1016\/j.jaci.2011.02.040","journal-title":"J Allergy Clin Immunol"},{"key":"836_CR6","doi-asserted-by":"publisher","first-page":"175628482110686","DOI":"10.1177\/17562848211068665","volume":"15","author":"S Feo-Ortega","year":"2022","unstructured":"Feo-Ortega S, Lucendo AJ (2022) Evidence-based treatments for eosinophilic esophagitis: insights for the clinician. Therapeutic Adv Gastroenterol 15:17562848211068665. https:\/\/doi.org\/10.1177\/17562848211068665","journal-title":"Therapeutic Adv Gastroenterol"},{"issue":"4","key":"836_CR7","first-page":"207","volume":"18","author":"EP Syverson","year":"2022","unstructured":"Syverson EP, Hait E (2022) Update on emerging pharmacologic therapies for patients with eosinophilic esophagitis. Gastroenterol Hepatol (N Y) 18(4):207\u2013212","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"2","key":"836_CR8","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.anai.2019.04.010","volume":"123","author":"ES Dellon","year":"2019","unstructured":"Dellon ES (2019) Cost-effective care in eosinophilic esophagitis. Ann Allergy Asthma Immunol 123(2):166\u2013172. https:\/\/doi.org\/10.1016\/j.anai.2019.04.010","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"836_CR9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1093\/jpepsy\/jsx128","volume":"43","author":"MK Lynch","year":"2018","unstructured":"Lynch MK, Barnes MJ, Dimmitt RA, Martin L, Rothenberg ME, Goodin BR (2018) Disease-related predictors of health-related quality of life in youth with eosinophilic esophagitis. J Pediatr Psychol 43(4):464\u2013471. https:\/\/doi.org\/10.1093\/jpepsy\/jsx128","journal-title":"J Pediatr Psychol"},{"issue":"6","key":"836_CR10","doi-asserted-by":"publisher","first-page":"853","DOI":"10.14309\/ajg.0000000000000597","volume":"115","author":"CC Reed","year":"2020","unstructured":"Reed CC, Corder SR, Kim E, Sanders E, Tappata M, Eluri S et al (2020) Psychiatric comorbidities and psychiatric medication use are highly prevalent in patients with eosinophilic esophagitis and associate with clinical presentation. Am J Gastroenterol 115(6):853\u2013858. https:\/\/doi.org\/10.14309\/ajg.0000000000000597","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"836_CR11","doi-asserted-by":"publisher","first-page":"e14069","DOI":"10.1111\/nmo.14069","volume":"33","author":"WE de Rooij","year":"2021","unstructured":"de Rooij WE, Evertsz B, Lei F, Bredenoord A (2021) Mental distress among adult patients with eosinophilic esophagitis. Neurogastroenterology Motil 33(7):e14069. https:\/\/doi.org\/10.1111\/nmo.14069","journal-title":"Neurogastroenterology Motil"},{"issue":"9","key":"836_CR12","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/j.cgh.2023.01.019","volume":"21","author":"C Mayerhofer","year":"2023","unstructured":"Mayerhofer C, Kavallar AM, Aldrian D, Lindner AK, M\u00fcller T, Vogel GF (2023) Efficacy of elimination diets in eosinophilic esophagitis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 21(9):2197\u2013210e3. https:\/\/doi.org\/10.1016\/j.cgh.2023.01.019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"836_CR13","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.3390\/nu15102409","volume":"15","author":"CM Rossi","year":"2023","unstructured":"Rossi CM, Lenti MV, Merli S, Cena H, Di Sabatino A (2023) Dietary strategies in adult patients with eosinophilic esophagitis: a state-of-the-art review. Nutrients 15(10):2409. https:\/\/doi.org\/10.3390\/nu15102409","journal-title":"Nutrients"},{"issue":"6","key":"836_CR14","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s10620-019-05602-w","volume":"64","author":"CC Cotton","year":"2019","unstructured":"Cotton CC, Durban R, Dellon ES (2019) Illuminating elimination diets: controversies regarding dietary treatment of eosinophilic esophagitis. Dig Dis Sci 64(6):1401\u20131408. https:\/\/doi.org\/10.1007\/s10620-019-05602-w","journal-title":"Dig Dis Sci"},{"issue":"1","key":"836_CR15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/2050640617707095","volume":"6","author":"AJ Lucendo","year":"2018","unstructured":"Lucendo AJ, Arias-Gonz\u00e1lez L, Molina-Infante J, Arias \u00c1 (2018) Determinant factors of quality of life in adult patients with eosinophilic esophagitis. United Eur Gastroenterol J 6(1):38\u201345. https:\/\/doi.org\/10.1177\/2050640617707095","journal-title":"United Eur Gastroenterol J"},{"issue":"12","key":"836_CR16","doi-asserted-by":"publisher","first-page":"3833","DOI":"10.1007\/s00405-015-3696-4","volume":"272","author":"H Larsson","year":"2015","unstructured":"Larsson H, Bergman K, Finizia C, Johansson L, Bove M, Bergquist H (2015) Dysphagia and health-related quality of life in patients with eosinophilic esophagitis: a long-term follow-up. Eur Arch Otorhinolaryngol 272(12):3833\u20133839. https:\/\/doi.org\/10.1007\/s00405-015-3696-4","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"24","key":"836_CR17","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/nejmoa2313318","volume":"390","author":"ME Rothenberg","year":"2024","unstructured":"Rothenberg ME, Dellon ES, Collins MH, Bredenoord AJ, Hirano I, Peterson KA et al (2024) Eosinophil depletion with benralizumab for eosinophilic esophagitis. N Engl J Med 390(24):2252\u20132263. https:\/\/doi.org\/10.1056\/nejmoa2313318","journal-title":"N Engl J Med"},{"issue":"1063","key":"836_CR18","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1136\/postgradmedj-2012-131403","volume":"90","author":"J Bystrom","year":"2014","unstructured":"Bystrom J, O\u2019Shea NR (2014) Eosinophilic oesophagitis: clinical presentation and pathogenesis. Postgrad Med J 90(1063):282\u2013289. https:\/\/doi.org\/10.1136\/postgradmedj-2012-131403","journal-title":"Postgrad Med J"},{"issue":"2","key":"836_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.gtc.2014.02.009","volume":"43","author":"GW Falk","year":"2014","unstructured":"Falk GW (2014) Clinical presentation of eosinophilic esophagitis in adults. Gastroenterol Clin N Am 43(2):231\u2013242. https:\/\/doi.org\/10.1016\/j.gtc.2014.02.009","journal-title":"Gastroenterol Clin N Am"},{"issue":"10","key":"836_CR20","doi-asserted-by":"publisher","first-page":"4458","DOI":"10.1007\/s12325-020-01463-2","volume":"37","author":"RM Pokrzywinski","year":"2020","unstructured":"Pokrzywinski RM, Harding G, Brooks A, Goodwin B, Williams J (2020) Documenting the journey of patients with eosinophilic esophagitis and the impact of the disease on patients and their caregivers: a cross-sectional, qualitative research study. Adv Therapy 37(10):4458\u20134478. https:\/\/doi.org\/10.1007\/s12325-020-01463-2","journal-title":"Adv Therapy"},{"issue":"12","key":"836_CR21","doi-asserted-by":"publisher","first-page":"5254","DOI":"10.1007\/s12325-023-02678-9","volume":"40","author":"H Larsson","year":"2023","unstructured":"Larsson H, Strobel MJ, Perez-Guagnelli E (2023) Emotional journey of patients with eosinophilic esophagitis. Adv Therapy 40(12):5254\u20135270. https:\/\/doi.org\/10.1007\/s12325-023-02678-9","journal-title":"Adv Therapy"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00836-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-025-00836-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00836-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T22:03:24Z","timestamp":1736373804000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-025-00836-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["836"],"URL":"https:\/\/doi.org\/10.1186\/s41687-025-00836-x","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"assertion":[{"value":"6 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This interview study was approved as part of the MESSINA clinical trial by the Institutional Review Boards (IRB)\/ethics committees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants voluntarily consented to be part of this study through informed consent form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All participants consented to publication of anonymized data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Authors CNH and HF are employees of AstraZeneca and may own stock\/stock options. Authors JB, SM, and JR are employees of IQVIA, which received funding from AstraZeneca for the conduct of this study. CS received research funding from AstraZeneca, EsoCap Biotech, Regeneron Pharmaceuticals Inc., Celldex Therapeutics, Adare Pharmaceuticals Inc., International marketing & Communication, S.A., and Dr. Falk Pharma GmbH; received honoraria as consultant and for providing training at AstraZeneca, Laborie\/MMS, Medtronic Covidien AG, Menarini Consumer Healthcare, Doctaforum Medical Marketing S.L., Isomed Pharma S.L., and Farma de Colombia SAS. ESD received research funding from Adare\/Ellodi, Allakos, Arena\/Pfizer, AstraZeneca, Eupraxia, Ferring, GSK, Meritage, Miraca, Nutricia, Celgene\/Receptos\/BMS, Regeneron, Revolo, and Shire\/Takeda; is a consultant for Abbott, Abbvie, Adare\/Ellodi, Aimmune, Akesobio, Alfasigma, ALK, Allakos, Amgen, Apollo, Aqilion, Arena\/Pfizer, Aslan, AstraZeneca, Avir, Biorasi, Bryn, Calypso, Celgene\/Receptos\/BMS, Celldex, Eli Lilly, EsoCap, Eupraxia, Dr. Falk Pharma, Ferring, GSK, Gossamer Bio, Holoclara, Invea, Knightpoint, Landos, LucidDx, Morphic, Nexstone Immunology\/Uniquity, Nutricia, Parexel\/Calyx, Phathom, Regeneron, Revolo, Robarts\/Alimentiv, Salix, Sanofi, Shire\/Takeda, Target RWE, and Upstream Bio; received educational grants from Allakos, Aqilion, Holoclara, and InveaInvea. MER is a consultant for Pulm One, Spoon Guru, ClostraBio, Serpin Pharm, Celldex, Uniquitybio, Santa Ana Bio, EnZen Therapeutics, Bristol Myers Squibb, AstraZeneca, Pfizer, GlaxoSmith Kline, Regeneron\/Sanofi, and Guidepoint; has an equity interest in Pulm One, Spoon Guru, ClostraBio, Serpin Pharm, Celldex, Uniquitybio, Santa Ana Bio, EnZen Therapeutics, and Allakos; has received royalties from reslizumab (Teva Pharmaceuticals), PEESSv2 (Mapi Research Trust) and UpToDate; is an inventor of patents owned by Cincinnati Children\u2019s Hospital.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}